MeSH D008654 - mesothelioma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008654:Â
Mesothelioma
D000086002:Malignant mesothelioma
D018261:Cystic mesothelioma
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Pemetrexed | Pemetrexed Accord |  | 2016-01-18 |  |  |
| Allergan | Pemetrexed | Armisarte (previously Pemetrexed Actavis) |  | 2016-01-18 |  |  |
| Baxter | Pemetrexed | Pemetrexed Baxter |  | 2022-12-09 |  |  |
| Bristol Myers Squibb | Nivolumab | Opdivo |  | 2015-06-19 | $8,885 M | Q2/23-Q1/24 |
| Eli Lilly | Pemetrexed | Alimta |  | 2004-09-20 | $217.5 M | Y2023 |
| Pemetrexed | Pemetrexed Lilly |  | 2015-09-14 |  |  | |
| Fresenius Kabi | Pemetrexed | Pemetrexed Fresenius Kabi |  | 2016-07-22 |  |  |
| Krka | Pemetrexed | Pemetrexed Krka |  | 2018-05-22 |  |  |
| medac | Pemetrexed | Pemetrexed medac |  | 2015-11-26 |  |  |
| Menarini | Pemetrexed | Ciambra |  | 2015-12-02 |  |  |
| Pfizer | Pemetrexed | Pemetrexed Pfizer (previously Pemetrexed Hospira) |  | 2015-11-19 |  |  |
| Pemetrexed | Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) |  | 2017-04-24 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
62%26/42
Phase 2
23%13/56
Phase 3
22%4/18
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use